Found 194 articles for: "psoriasis"
Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis
August 2026 | Volume 25 | Issue 8 | Original Article | 695 | Copyright © August 2026
Background: People with psoriasis are at increased risk for nonmelanoma skin cancers (NMSC) and melanoma. Conventional immunosuppressants and TNF-α inhibitors may further i...
Read MoreImpact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol
August 2026 | Volume 25 | Issue 8 | Original Article | 742 | Copyright © August 2026
Background: Psoriasis is a chronic immune‑mediated inflammatory skin disease that is strongly associated with metabolic dysregulation and excess adiposity. Dietary strategies t...
Read MoreImproved Sleep Quality in Psoriasis Patients Under Biologicals: A Prospective Observational Study
August 2026 | Volume 25 | Issue 8 | Original Article | 726 | Copyright © August 2026
Background: Sleep disorders are an underappreciated component of psoriasis-related morbidity. Biologic therapies targeting IL-17 and IL-23 may improve sleep quality by reducing s...
Read MoreGLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity
August 2026 | Volume 25 | Issue 8 | Features | 753 | Copyright © August 2026
Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis
August 2026 | Volume 25 | Issue 8 | Original Article | 686 | Copyright © August 2026
Background: Psoriasis is a chronic inflammatory condition affecting approximately 3% of adults in the United States (US). While biologic therapies have transformed treatment for ...
Read MoreHidradenitis Suppurativa in Psoriasis Patients Treated With Biologics
August 2026 | Volume 25 | Issue 8 | Editorials | e75 | Copyright © August 2026
Assessing Accuracy of ChatGPT in Identifying Contact Allergens in Commonly Prescribed Topical Therapies for Psoriasis
August 2026 | Volume 25 | Issue 8 | Editorials | 758 | Copyright © August 2026
Comprehensive Analysis of Comorbidities Associated With Psoriasis Diagnosis in the MEPS National Cohort
August 2026 | Volume 25 | Issue 8 | Editorials | 760 | Copyright © August 2026
Risankizumab Associated With Lower Incident Depression and Sleep Disorders in Psoriasis: A TriNetX Study
August 2026 | Volume 25 | Issue 8 | Editorials | 762 | Copyright © August 2026
Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature
April 2026 | Volume 25 | Issue 4 | Original Article | 324 | Copyright © April 2026
Background: Many patients with psoriasis suffer from post-inflammatory pigmentary alteration (PIPA), which remains an unmet treatment need. Eruptive lentiginosis (EL) is a rare f...
Read MoreBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreChatGPT and DeepSeek in Dermatologic Practice: Do Artificial Intelligence Models Adhere to Psoriasis Treatment Guidelines?
February 2026 | Volume 25 | Issue 2 | Original Article | 133 | Copyright © February 2026
Background: The integration of artificial intelligence (AI), particularly large language models (LLMs), into healthcare has rapidly expanded. In dermatology, machine learning is ...
Read MoreReal-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis
February 2026 | Volume 25 | Issue 2 | Original Article | 126 | Copyright © February 2026
Brodalumab is a recombinant, fully human monoclonal antibody antagonist of the human interleukin-17 (IL-17) receptor A. It is indicated for the treatment of moderate-to-severe plaque psoriasis in...
Read MoreMore Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis
December 2025 | Volume 24 | Issue 12 | Original Article | 1231 | Copyright © December 2025
Psoriasis has profound negative impacts on quality of life (QOL), including stigmatization, discrimination, occupational challenges, and mental health concerns, which are correlated with disease ...
Read MoreResolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene
August 2025 | Volume 24 | Issue 8 | Original Article | 795 | Copyright © August 2025
Background: Hyperkeratotic plaque psoriasis represents a distinct morphological variant that is difficult to treat with topical therapies because thick lesions may impede the pen...
Read MoreOpen-Label Study: Over-the-Counter Oat Flour/Oat Oil/ Oat Extract-containing Lotion With Avenanthramides for Sensitive Skin and Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 782 | Copyright © August 2025
Read MoreStudy of Adjuvant Sensitive-Skin Cleansing and Moisturizing Regimen in Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 739 | Copyright © August 2025
Read MoreHalobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance
August 2025 | Volume 24 | Issue 8 | Original Article | 752 | Copyright © August 2025
Scalp involvement in plaque psoriasis is accompanied by itching and scaling that reduce quality of life and exacerbate psoriatic-associated hair loss. Challenges for the topical treatment of scal...
Read MoreComparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison
August 2025 | Volume 24 | Issue 8 | Original Article | 788 | Copyright © August 2025
Background: Plaque psoriasis of the scalp, a common psoriasis location, remains difficult to manage. The comparative efficacy of newer oral agents, such as deucravacitinib, versus ...
Read MoreChatGPT Improves Readability of Patient Education Materials for Hidradenitis Suppurativa and Psoriasis
August 2025 | Volume 24 | Issue 8 | Features | 828 | Copyright © August 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
